Adoption of Telemedicine and Digital Healthcare Solutions
Revolutionizing Rosacea Treatment by Facilitating Remote
Consultations for Patients.
ROCKVILLE, Md., July 3, 2024
/PRNewswire/ -- According to a recently released research report by
Fact.MR, the global Rosacea Therapeutics Market is
expected to reach US$ 4.65
billion in 2024 and is thereafter projected to expand at
a CAGR of 6.1% from 2024 to 2034. Advancements in the
rosacea treatment industry are being driven by the increasing use
of digital health interventions. By the end of 2034, the market is
projected to reach US$ 8.41
billion in value.
The growing adoption of telemedicine and digital healthcare
solutions is transforming rosacea treatment, enabling remote
consultations, follow-ups, and patient monitoring. These
innovations enhance patient compliance and expand access to
specialized treatments, particularly in underserved areas.
Additionally, ongoing research and development efforts are poised
to introduce cutting-edge treatments for rosacea, including novel
oral medications, laser technologies, and topical formulations.
The rise in global healthcare spending is creating a favorable
environment for providers of rosacea therapeutics providers. As
healthcare investments increase, people gain better access to
medical treatments, including rosacea diagnosis and therapy.
Heightened awareness campaigns and educational programs about
rosacea symptoms and treatments are leading to earlier diagnosis
and intervention, driving the rosacea treatment market share.
For More Insights into the Market, Request a Sample of this
Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=10190
Key Takeaways from the Rosacea Therapeutics Market
Study:
- The market in Japan is
projected to reach US$ 208 million in
2024.
- Demand for rosacea therapeutics in the United States is forecasted to rise at a
CAGR of 6.7% from 2024 to 2034.
- China is set to capture a
market share of 55.1% in East Asia
in 2024.
- Sales of antibiotics for rosacea treatment are set to reach
US$ 1.84 billion in 2024.
"Increasing healthcare investments improve access to
rosacea therapeutics is driving market growth. Healthcare providers
and governments are striving to enhance accessibility to
specialized treatments, especially in underprivileged
areas," says a Fact.MR analyst.
Pharmaceutical Companies Seeking Regulatory Approvals to
Introduce Innovative Rosacea Treatments
Increasing awareness among the population is boosting the demand
for rosacea therapeutics, resulting in more accurate diagnosis and
treatment of rosacea cases in Japan. Pharmaceutical companies are seeking
regulatory approval for their existing rosacea treatments and
introducing new ones to expand their product offerings in the
Japan market. Consequently,
patients and medical professionals now have more options for
treating rosacea symptoms, driving the rosacea therapeutics market
growth.
Rosacea Therapeutics Industry News:
Key players in the rosacea treatment market are expanding
accessibility and uptake of cutting-edge treatments. Oral
antibiotics and topical antibiotic creams have long been the
mainstays of rosacea treatment. However, there have been
significant advancements in the creation of more specialized
treatments in recent years. Novel therapeutics have emerged that
target important inflammatory pathways involved in the
pathophysiology of rosacea, such as monoclonal antibodies.
- In May 2022, the United States
Food and Drug Administration (FDA) approved ZILXI
(minocycline) topical foam, 1.5%, for the treatment of inflammatory
lesions of rosacea in adults. This approval was reported by VYNE
Therapeutics Inc., a specialty pharmaceutical company focused on
developing and commercializing proprietary therapies to address
unmet needs in dermatology.
- In June 2021, Teva
Pharmaceuticals, an affiliate of Teva Pharmaceutical Industries
Ltd., launched a generic version of SOOLANTRA (ivermectin) Cream,
1%, for treating rosacea.
Get Customization on this Report for Specific Research
Solutions:
https://www.factmr.com/connectus/sample?flag=S&rep_id=10190
Leading Players Driving Innovation in the Rosacea
Therapeutics Market:
- Gary Pharmaceuticals P Limited
- Glenmark Pharmaceuticals
- Cipla Ltd.
- VYNE Therapeutics
- Galderma
- Bayer AG
- Bausch Health Companies Inc.
- Hovione
- Pfizer Inc.
- PruGen Pharmaceuticals
- AbbVie, Inc.
- Eckson Labs
- Sandoz Spa
- Abigail Care Pharmaceutical
More Valuable Insights:
Fact.MR, in its new offering, presents an unbiased analysis of
the rosacea therapeutics market for 2019 to 2023 and forecast
statistics for 2024 to 2034.
The study divulges insights into the rosacea therapeutics market
based on disease (erythematotelangiectatic rosacea, papulopustular
rosacea, ocular rosacea, phymatous rosacea), drug class
(antibiotics, immunosuppressants, corticosteroids), route of
administration (oral, topical), treatment (oral antibiotics,
topical treatment, eye drops & lubricants, other drugs
including methotrexate & ivermectin, laser therapy), and
distribution channel (institutional sales, retail sales, online
sales), across seven major regions of the world (North America, Latin
America, Western Europe,
Eastern Europe, East Asia, South
Asia & Pacific, and MEA).
Explore More Related Studies Published by Fact.MR
Research:
Skin Barrier Market is estimated to reach a valuation of
$540.9 million by 2034, projected at
a CAGR of 3.8% from 2024 to 2034.
Peptide-based Metabolic Disorders Therapeutics Market is
forecasted to increase at a stellar CAGR
of 12% from 2023 to 2033.
Peptide-based Infection Therapeutics Market stands at a
valuation of $1.98 billion in 2023 and is predicted to
amass a revenue of $4.4 billion by 2033.
Peptide Based Hematological Disorders Therapeutics Market will
touch a value of nearly $530 Mn in the year 2022 and grow
at a robust CAGR during the assessment period.
Therapeutic Support Surface Market is set to witness a 6.2%
growth during the year 2021-2031.
Antibiotic residue test kits market is reaching a valuation of
$333.4 Min by 2033. sales of
sulfonamide test kits are forecasted to rise at 7% CAGR.
Tricuspid valve repair market is forecasted to reach a valuation
of US$ 487.2 Mn by 2034, up from
$224 Mn in 2024, with a CAGR of 8.1%
by 2034.
Skincare Serums Market is expected to be worth $6.28 Bn by 2032, and it is expected to grow at a
CAGR of 7.4% by 2032.
About Us:
Fact.MR is a distinguished market research company
renowned for its comprehensive market reports and invaluable
business insights. As a prominent player in business intelligence,
we deliver deep analysis, uncovering market trends, growth paths,
and competitive landscapes. Renowned for its commitment to accuracy
and reliability, we empower businesses with crucial data and
strategic recommendations, facilitating informed decision-making
and enhancing market positioning.
With its unwavering dedication to providing reliable market
intelligence, FACT.MR continues to assist companies in navigating
dynamic market challenges with confidence and achieving long-term
success. With a global presence and a team of experienced analysts,
FACT.MR ensures its clients receive actionable insights to
capitalize on emerging opportunities and stay
competitive.
Contact:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Sales Team: sales@factmr.com
Follow
Us: LinkedIn | Twitter | Blog
View original
content:https://www.prnewswire.com/news-releases/rosacea-therapeutics-market-to-reach-a-value-of-8-41-billion-growing-at-a-cagr-of-6-1-by-2034--302188950.html
SOURCE Fact.MR